D&D Pharmatech Raises $165M as MASH Drug DD01 Approaches Key Phase 2 Readout
核心洞察
D&D Pharmatech (搜索) completed a $165 million convertible bond issuance to accelerate development of its MASH (搜索) drug DD01 and pipeline expansion.
The company's shares surged 14% on expectations for 48-week tissue biopsy results from DD01's Phase 2 trial to be presented at EASL.
DD01, a dual GLP-1 (搜索)/glucagon receptor (搜索) agonist, showed early signals of liver fat reduction and fibrosis improvement in U.S. patients at 12 and 24 weeks.
D&D Pharmatech (搜索) has secured $165 million in funding through a convertible bond issuance as the Korean biotech company prepares to unveil pivotal 48-week biopsy results from its Phase 2 trial of MASH (搜索) drug candidate DD01 at the upcoming European Association for the Study of the Liver (EASL) congress.
The company's shares jumped 14.33% to 69,400 won on Tuesday, reflecting investor optimism ahead of the clinical data presentation. The funding round, which exceeded the original target, was led by DS Investment Partners (搜索) with participation from domestic asset management firms and international investors including Weiss Asset Management (搜索) and Tybourne Capital (搜索).
DD01 Shows Early Promise in MASH Treatment
DD01 is a dual agonist that simultaneously targets glucagon-like peptide (GLP)-1 and glucagon receptors. In the ongoing Phase 2 trial conducted on U.S. patients, the drug demonstrated encouraging signals of rapid liver fat reduction and improvement in liver fibrosis (搜索) at both the 12-week and 24-week evaluation points.
The market is now focused on whether these early positive signals will achieve statistical validation in the comprehensive 48-week tissue biopsy analysis, which represents a critical milestone for the program's advancement.
Strategic Positioning in Hot MASH Market
The timing of D&D Pharmatech (搜索)'s funding aligns with intense industry interest in metabolic dysfunction-associated steatohepatitis (搜索) treatments. Global pharmaceutical companies have been making substantial investments in this therapeutic area, with recent high-profile acquisitions demonstrating the market's potential value.
Last year, Roche acquired 89bio for up to $3.5 billion to secure rights to the MASH (搜索) drug pegozafermin, while Novo Nordisk paid up to $5.2 billion for Akero Therapeutics to obtain efruxifermin. These transactions underscore the significant commercial opportunity that successful MASH therapies represent.
Pipeline Expansion and Development Acceleration
Beyond DD01, D&D Pharmatech (搜索) plans to use the new funding to accelerate development of its broader pipeline. The company has identified TLY012, a fibrosis treatment, as a next-generation core growth driver and aims to initiate clinical trials for liver fibrosis (搜索) treatment as early as next year.
The funding will also support discovery efforts based on the company's ORALINK platform and advancement of next-generation obesity (搜索) treatments, expanding D&D Pharmatech (搜索)'s presence in metabolic disease therapeutics.
Leadership Confidence in Clinical Success
"The completion of this CB payment goes beyond simple fundraising. I believe it reaffirms the market's confidence in the clinical success potential of DD01 and the company's growth potential," said D&D Pharmatech (搜索) CEO Lee Seul-gi.
The CEO emphasized the company's commitment to leveraging positive Phase 2 clinical results to pursue meaningful partnering opportunities in the global market, positioning DD01 for potential licensing discussions if the 48-week biopsy data confirms the drug's therapeutic benefit.
The convertible bonds were structured with 0% coupon rate and yield to maturity, including a one-year restriction on resale and conversion, reflecting investor confidence in the company's clinical prospects and growth trajectory.